Posted on: Mar 10, 2019 01:51PM
Molecular breast imaging (MBI), a nuclear medicine test performed with the radiotracer Tc-99m sestamibi and a dedicated gamma camera, has shown utility for supplemental screening in women with dense breasts on mammography. Because mammography relies on the differences in X-ray attenuation among breast structures to detect cancer, tumors can be masked by surrounding fibroglandular tissue. Fibroglandular tissue of the breast, called breast density when imaged by mammography, has similar X-ray attenuation properties to tumors. In contrast, MBI depicts preferential uptake of Tc-99m sestamibi in metabolically active cells and is able to reveal cancers obscured by density on mammography. In recent studies, the addition of MBI to mammography in women with dense breasts resulted in an additional 7.7 to 8.8 cancers per 1000 women screened [1, 2].
Has anyone heard of above? https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-019-1120-5Log in to post a reply